Lori Melançon joined Rubius as Vice President of Corporate Communications and Investor Relations in June 2018. She brings 20 years of experience working with biotechnology companies to tell their stories to investors, media, patient advocacy organizations and employees. Prior to her role at Rubius, she was the Head of Corporate Affairs at Onyx Pharmaceuticals, an Amgen subsidiary, where she served on the leadership team and led a high-performing team of communications professionals who managed corporate communications, global product communications, global patient advocacy, social/digital media and employee communications and provided investor relations support to Amgen for Onyx Pharmaceuticals.
Earlier in her career, she held corporate, product and marketing communications positions at WeissComm Partners, now W2O Group, a healthcare communications agency, Applied Biosystems, now Thermo Fischer Scientific, and ReGen Biologics, now Ivy Sports Medicine. She began her career working on political campaigns in her home state of California.
Lori holds an MBA from the University of San Francisco and a B.A. in Rhetoric and Communications from the University of California, Davis.